triptorelin

P=N/A, N=450, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P2, N=25, Recruiting, H. Lee Moffitt Cancer Center and Research Institute

P=N/A, N=10, Not yet recruiting, ART Fertility Clinics LLC

P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: May 2028 --> Jun 2025

P=N/A, N=0, Withdrawn, Sir Mortimer B. Davis - Jewish General Hospital | N=65 --> 0 | Not yet recruiting --> Withdrawn

P3, N=784, Recruiting, The University of Hong Kong | Trial completion date: Dec 2024 --> Mar 2025

P2, N=130, Completed, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Dec 2024

P2/3, N=102, Active, not recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Apr 2027

P3, N=53, Recruiting, Debiopharm International SA | Trial completion date: Dec 2027 --> Mar 2028 | Trial primary completion date: Jul 2026 --> Dec 2026

P=N/A, N=42, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed

The findings of the current study demonstrated that the simultaneous consumption of a certain amount of broccoli extract and SI can be considered as a promising therapeutic strategy for treatment of endometriosis.

P=N/A, N=48, Enrolling by invitation, Hospital de Niños R. Gutierrez de Buenos Aires

P1, N=120, Recruiting, The Affiliated Hospital of Qingdao University

P2, N=149, Completed, European Organisation for Research and Treatment of Cancer - EORTC | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024

Subsequently, he received androgen deprivation therapy (ADT) for 6 months with triptorelin and bicalutamide...The pathological stage was pT1c pN1mi.The Oncotype DX study had a Recurrence Score (RS) of 22 points, leading to a recommendation for adjuvant chemotherapy with Docetaxel-Cyclophosphamide for 4 cycles, followed by tamoxifen...Early detection through screening and appropriate medical follow-up improves the prognosis in patients carrying PV in BRCA2. Therefore, risk control monitoring and adequate genetic counseling are necessary.

P=N/A, N=167, Completed, Ipsen | Recruiting --> Completed | N=300 --> 167

P=N/A, N=419, Recruiting, Ipsen | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026

P2, N=176, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: May 2028 --> Feb 2028

P=N/A, N=36, Recruiting, Insel Gruppe AG, University Hospital Bern | Phase classification: P2 --> P=N/A

P3, N=53, Recruiting, Debiopharm International SA | Trial completion date: Sep 2027 --> Dec 2027

P=N/A, N=184, Completed, Zagazig University

P3, N=195, Completed, Ipsen | Active, not recruiting --> Completed

P=N/A, N=300, Recruiting, Ipsen | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024

P3, N=147, Completed, Ipsen | Active, not recruiting --> Completed

P2, N=32, Not yet recruiting, OHSU Knight Cancer Institute

BE in combination with SI decreased the growth and histopathologic grades of transplanted endometrial implants. These herbal compounds may have the potential therapeutic effect to be used as an alternative medication for the treatment of endometriosis.

P2, N=32, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jul 2028 | Trial primary completion date: Jan 2027 --> Jul 2027

P3, N=60, Not yet recruiting, Children's Oncology Group

Herein, we present the first case ever reported, concerning a female patient with de novo metastatic breast NEC who received hormonal therapy, a combination of a CDK4/6 inhibitor palbociclib with letrozole and triptorelin, as first-line treatment with significant clinical and radiological response. As most NECs are estrogen receptor and/or progesterone receptor positive and HER-2 negative, we suggest that hormonal therapy may play a leading role even in the first-line setting. The present report provides a new treatment strategy by incorporating CDK4/6 inhibitors in the therapeutic armamentarium of breast NECs.

P3, N=694, Active, not recruiting, Janssen Pharmaceutica N.V., Belgium | Recruiting --> Active, not recruiting | N=412 --> 694

P=N/A, N=166, Completed, Universitaire Ziekenhuizen KU Leuven | Unknown status --> Completed

P4, N=134, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P2, N=120, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting

P4, N=60, Not yet recruiting, University Hospital, Ghent | Initiation date: Apr 2024 --> Jul 2024

P3, N=53, Recruiting, Debiopharm International SA | Initiation date: Apr 2024 --> Jul 2024

P2, N=176, Active, not recruiting, Hoffmann-La Roche | N=550 --> 176

P2, N=19, Active, not recruiting, University of Colorado, Denver | Trial completion date: Apr 2024 --> Apr 2025

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

P2, N=120, Not yet recruiting, Mayo Clinic

P2, N=550, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

P=N/A, N=42, Active, not recruiting, Medical College of Wisconsin | N=60 --> 42

P2, N=61, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: May 2024 --> Dec 2036